Optomed Plc Stock Exchange Release 23 September 2025 at 9.00, Helsinki

Optomed's Board has resolved upon a new option plan

Optomed's board of directors has resolved upon a new option plan. The resolution is based on the authorization given by the general meeting of 9 May 2025.

Option plan 2025A:

The total number of options is 190,000 and each option entitled to one share of the company. The options are offered to certain key employees. The purpose of the plan is to retain and incentifize the CEO and certain other key employees. The subscription price is EUR 3.77. The subscription price is based on the average closing prices of the last 30 trading days on Nasdaq Helsinki. The subscription period is 1 January 2027 - 31 December 2029.

The theoretical market value of one option under the plan 2025A is approximately EUR 0.806 per stock option and the theoretical total market value of the plan 2025A is approximately 153,140 euros in total. The theoretical market value of a stock option has been calculated by using the Black & Scholes stock option pricing model with the following input factors: share price EUR 3.69 euros, subscription price EUR 3.77 risk free interest rate 3.11%, validity of stock options approximately 3 years and volatility 47.4%.

The complete terms and conditions of the option plan 2025A are attached to this release.

Optomed Plc

Further enquiries

Petri Salonen, Chairman, Optomed Plc, petri.salonen@optomed.com

Optomed in Brief 

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.

www.optomed.com